Kimme L. Hyrich
University of Manchester
414 Papers
841 Citations
Kimme L. Hyrich is an academic researcher from University of Manchester. The author has contributed to research in topics: Medicine & Rheumatoid arthritis. The author has an hindex of 58, co-authored 305 publications. Previous affiliations of Kimme L. Hyrich include Health Science University & University of Toronto.
Chat about Author
Papers
Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study
Ahmad A Sherbini,James M. Gwinnutt,Adedeji David Adebajo,Khalid Ahmed,A G Al-Ansari,Roshan Amarasena,Marwan Bukhari,M. Callan,Easwaradhas Gladstone Chelliah,Hector Chinoy,Annie Cooper,Bhaskar Dasgupta,Martin Davis,James N. Galloway,Andrew Gough,Michael Green,Nicola J. Gullick,J. Hamilton,W Hassan,Samantha L. Hider,Kimme L. Hyrich,Sanjeet Kamath,Susan Knight,SE Lane,Martin Lee,Sarah Levy,Lizzy Macphie,C. Marguerie,Tom Marshall,Catherine J Mathews,Frank McKenna,Sophia M. Naz,Mark G. Perry,Louise C. Pollard,Brian Quilty,Lindsay Robertson,D.K. Roy,Paul Sanders,Vadivelu Saravanan,David Scott,Gillian L F Smith,Richard D. Smith,Deborah P M Symmons,Lee Suan Teh,N. Viner,Suzanne M M Verstappen +45 more
TL;DR: Prevalence rates and baseline predictors of adverse events (AEs) over the first year of treatment in patients with RA starting MTX were estimated to help patients make informed decisions whether to start MTX, potentially increasing adherence to treatment.
19
Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study
TL;DR: ETN therapy was associated with an improvement in height z-score over the first 2 years of therapy in this real-world cohort of children with severe JIA, and the lack of a strong association of improvements in height with improvements in disease activity warrants further exploration.
19
Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
Audrey S. L. Low,Mark Lunt,Louise K. Mercer,Kath D. Watson,William G Dixon,Deborah P M Symmons,Kimme L. Hyrich +6 more
TL;DR: Patients with rheumatoid arthritis are at an increased risk of ischemic stroke and Tumor necrosis factor inhibitors (TNFi) may influence risk and mortality after isChemic stroke by reducing inflammation.
19
Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy.
James M. Gwinnutt,Sam Norton,Kimme L. Hyrich,Mark Lunt,Anne Barton,Lis Cordingley,Suzanne M M Verstappen,Rams co-investigators +7 more
TL;DR: The Negative group had worse disability, pain and fatigue over follow-up compared with the other groups, controlling for inflammation, and illustrated that illness perceptions can change in RA.